World Health Organization Sounds Concern Over Severe Scarcity of Obesity Medications
Less than a tenth of people eligible to benefit from GLP-1 drugs including Wegovy can access them, states the WHO as it releases its inaugural guidance on the medications.
With in excess of 1,000,000,000 individuals worldwide currently obese, it is urging more widespread and fairer access to these injectable treatments.
Based on forecasts, over two billion are projected to be obese by 2030 without intervention.
"Our new guidelines affirms that excess weight is a lifelong illness that can be addressed with holistic and continuous treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are significant barriers to broad access to the treatments that can help people shift substantial weight, notes the body.
GLP-1 Therapy Supply Crisis
Despite the current best projected outlook, the manufacturing of such drugs might only reach around 100 million people – fewer than 10% of the global need, per the health organization.
The advice calls on countries and companies to expand availability, by strategies including licensing agreements.
The intellectual property rights on semaglutide – the primary ingredient of Novo Nordisk's Wegovy – is due to expire in a number of nations in 2026.
The Way Weight-Loss Drugs Operate
The injections replicate a natural hormone to slow digestion, curb appetite and enhance satiety so users consume fewer calories.
Patients typically begin shedding pounds in the initial weeks of starting on the weekly injections.
Evidence indicates patients may put most of the weight back on a year later of halting the medication, as their normal appetite resume.
To be overweight or obese increases your likelihood for experiencing diseases, including diabetes, heart disease, brain attack, and specific malignancies.
Excess weight concerns people in every country and was associated with over three and a half million deaths worldwide in 2024, as per the WHO.
